In Brief: NeXstar Ambisome
Executive Summary
NeXstar Ambisome: Liposomal amphotericin B formulation NDA accepted by FDA for review, Boulder, Colo.-based NeXstar and marketing and development partner Fujisawa USA say Jan. 13. The application is for the treatment in a variety of fungal disease settings and includes data from over 1,000 patients and 12 clinical trials...